Last $1,026 MXN
Change Today 0.00 / 0.00%
Volume 0.0
BAX* On Other Exchanges
SIX Swiss Ex
As of 4:09 PM 02/24/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX*) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/11/14 - $1,079
52 Week Low
03/18/14 - $890.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

baxter international inc (BAX*) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX*) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX*) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $687.7K
Corporate Vice President and President of Bio...
Total Annual Compensation: $742.3K
Compensation as of Fiscal Year 2013.

baxter international inc (BAX*) Key Developments

Baxter International Inc. Announces Quarterly Dividend, Payable on April 1, 2015

The Board of Directors of Baxter International Inc. declared a quarterly dividend of $0.52 per Baxter common share. The dividend is payable on April 1, 2015 to shareholders of record as of March 11, 2015.

Baxter Provides Progress Update on Gene Therapy Program

Baxter International Inc. provided an update on its gene therapy program, including progress on the Phase I/II open-label clinical trial assessing the safety and optimal dosing level of BAX 335, an investigational factor IX (FIX) gene therapy treatment for hemophilia B, during a sponsored symposium at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland. The trial is assessing the safety of ascending doses of BAX 335 to determine the optimal single dose in up to 16 adult patients with hemophilia B at treatment centers in the United States. The primary endpoint is the safety of a single dose of BAX 335 administered intravenously. Secondary endpoints include evaluation of the optimal dose to achieve stable therapeutic plasma FIX activity, as well as pharmacokinetics and immune response to treatment. As of the end of 2014, a total of six patients in three dosing cohorts have been treated in the trial with evidence of a dose-related response. No patients have developed FIX inhibitors to date. In the two higher dose cohorts, FIX activity levels around 10% or above have been observed in two patients, who also experienced no bleeding events. One of these patients showed elevated levels of liver enzymes indicative of an immune response, which is being treated with oral corticosteroids, per protocol. Immune responses have been reported in previous studies with gene therapy technology.

Baxter International Inc. Presents Additional Efficacy and Safety Data from the Phase III Pivotal Study of BAX 855

Baxter International Inc. presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)] at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland. The new data expand on the previously disclosed topline results from the pivotal trial, which found that BAX 855 met the study's primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis. Patients in the twice-weekly prophylaxis arm of the trial experienced a 95% reduction in median annualized bleed rate (ABR) as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). The study findings supported Baxter's December 2014 submission for approval of BAX 855 to the United States Food and Drug Administration. The prospective, global, multi-center, open-label, two-arm Phase III study evaluated BAX 855 among 137 previously treated hemophilia A patients (PTP) who were 12 years or older. Patients were assigned either to twice weekly prophylaxis (40-50 IU/kg, n=120) or on-demand treatment (10-50 IU/kg, n=17). In addition to a reduced ABR, BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions at a median dose of 29.0 IU/kg per infusion. Treatment was rated excellent or good for nearly all episodes (96.2%). In the prophylactic group (n=101), 40% of patients experienced no bleeds. The study also showed that BAX 855 pharmacokinetics offered a 1.4-1.5-fold extended half-life compared to ADVATE with a median infusion interval of 3.6 days, supporting the findings from the Phase I trial. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. Seven adverse reactions in six patients, including headache, diarrhea, nausea, and flushing were reported. Baxter's continuation study for patients who completed the pivotal trial and the Phase 3 study among previously treated patients under the age of 12 with severe hemophilia A remain ongoing. Upon completion of the pediatric study, Baxter expects to file for marketing authorization with the European Medicines Agency in 2016. BAX 855 is based on ADVATE, a full-length FVIII molecule with more than 11 years of real-world patient experience. Through a collaboration with Nektar Therapeutics, BAX 855 leverages proprietary PEGylation technology designed to prolong the amount of factor VIII available for use in the body. This proprietary technology has been used for 15 years in a number of approved medicines that treat chronic or serious conditions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX*:MM $1,026.31 MXN 0.00

BAX* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,901 JPY +3.00
CSL Ltd A$92.71 AUD +0.465
Kimberly-Clark Corp $109.66 USD -0.25
Stryker Corp $94.75 USD +0.35
Takeda Pharmaceutical Co Ltd ¥6,123 JPY +15.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BAX* Industry Range
Price/Earnings 19.4x
Price/Sales 2.2x
Price/Book 4.5x
Price/Cash Flow 15.0x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at